Press Detail

/
Ad-hoc RELEASE
Announcement according to Article 17 European Market Abuse Regulation (MAR)

Tender Offer by Tiancheng (Germany) Pharmaceutical Holdings AG / Tiancheng withdrawal of application of transaction from CFIUS and refiling

Dreieich, 7 November 2017 - The Committee on Foreign Investment in the United States ("CFIUS") which currently reviews the tender offer by Tiancheng (Germany) Pharmaceutical Holdings ("Tiancheng"), an affiliate of Creat Group Corporation, from a U.S. national security perspective informed the parties in writing that that the tender offer by Tiancheng to the shareholders of Biotest AG raises national security concerns of the U.SCFIUS did not issue a close-out letter, but informed the parties that it assumes at this point in time that the U.S. national security concerns cannot be mitigated under the current transaction structure.

Both parties, Tiancheng and Biotest AG decided to withdraw their notice and to refile a new application with the request for an expedited review period.

Biotest AG and Tiancheng plan to continue to actively engage in further discussions with CFIUS to explore means of mitigation that may be amenable to CFIUS to resolve outstanding U.S. national security concerns or to take other alternative measures that could allow the parties to proceed with the transaction. Creat Group Corporation confirmed its further support for Biotest and its continuing interest in a takeover of the shares in the company.

There are no assurances that CFIUS will shorten the review period or that the parties will be able to identify and agree to any mitigation or to take alternative measures that will allow the parties to proceed with the transaction.

Biotest Aktiengesellschaft
Board of Management

Biotest AG
Landsteinerstr. 5
D-63303 Dreieich
www.biotest.com

Disclaimer
This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.

About Biotest
Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. In addition Biotest develops monoclonal antibodies in the indications of cancer of plasma cells and systemic lupus erythematosus which are produced by recombinant technologies. Biotest has more than 2,500 employees worldwide. The preference shares of Biotest AG are listed in the SDAX on the Frankfurt stock exchange.

IR contact
Dr. Monika Buttkereit
phone: +49-6103-801-4406
email: investor_relations@biotest.de

PR contact
Dirk Neumüller
phone: +49-6103-801-269
email: pr@biotest.com

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com

Ordinary shares: securities' ID No. 522720; ISIN DE0005227201
Preference shares: securities' ID No. 522723; ISIN DE0005227235
Listing: Frankfurt, Prime Standard
Open Market: Berlin, Düsseldorf, Frankfurt, Hamburg, Hannover, Munich, Stuttgart, Tradegate Exchange